SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is experiencing heightened volatility as it tests critical support levels, sparking intense debate about whether the recent dip signals a buying opportunity or the start of a deeper bear market. Community discussions range from long-term bullish outlooks and disbelief to concerns about market manipulation and the potential for further declines. Traders are closely watching key levels and government actions.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto market experiences volatility, leading to community debates about potential bottom prices and future direction. Discussions range from frustration over recent price drops to optimism surrounding Ripple's ongoing developments and upcoming events like Ripple Swell. Some traders are expressing concerns about market manipulation and the impact of broader economic factors, including the government shutdown.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir (PLTR) is trending amidst a debate over its valuation following earnings and news of Michael Burry's short position, with CEO Alex Karp's response adding fuel to the fire. The community is split between those defending the company's growth potential in AI and those concerned about high multiples, especially given Burry's bet against the stock.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is experiencing renewed selling pressure, with community members closely watching the 200-day moving average as a key support level. Bearish sentiment seems to be rising with some traders anticipating further declines, while others are using the dip as a buying opportunity, and institutions are being observed for dip buying. Discussions include potential ETF outflows and concern regarding its correlation with equities.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

HTZ is trending as traders discuss its potential for a short squeeze and draw comparisons to other meme stocks like BYND and CVNA. Some are pointing to high short interest and recent earnings as potential catalysts, while others highlight the company's turnaround story and partnership with Amazon. The community is closely watching price action, anticipating a breakout above key resistance levels.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Despite positive analyst ratings and potential tailwinds from lower oil prices, NCLH is experiencing a downturn, sparking frustration among investors. Community sentiment suggests disappointment with management's actions and potential market manipulation affecting the stock's performance. Discussions revolve around whether the stock's current valuation presents a buying opportunity or if further declines are expected, with some traders looking to swing trade the volatility.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the crypto market experiences volatility, sparking debates about whether this is a temporary dip or the start of a longer downturn. Community sentiment is mixed, with some investors doubling down and hoping for a rally, while others express concerns about potential losses. The conversation also includes speculation about Elon Musk's involvement and the future integration of Dogecoin with X payments.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy ($MSTR) is trending as investors debate its correlation with Bitcoin's price movements and discuss its high valuation. Community members are analyzing potential support levels, expressing concerns about dilution, and speculating on future price targets. The stock's connection to the crypto market and Michael Saylor's strategy are key points of discussion.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending amid discussions around its autonomous vehicle strategy and partnerships, particularly with Nvidia and Lucid, as well as its potential for growth in the robotaxi market. Community members are debating the impact of these developments on Uber's competitive position and profitability, especially in light of Tesla's advancements in self-driving technology. Some analysts maintain a bullish outlook, citing strong bookings and potential for long-term growth, while others express concern about valuation and market manipulation.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending as the crypto market experiences volatility, leading to community frustration and debates over its potential. Some traders express concerns about JASMY's underperformance compared to other cryptocurrencies and its ranking, while others highlight accumulation patterns and anticipate a future surge. Discussions also include the impact of broader market factors and potential partnerships.

statis crypto Watchlist

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Pasithea Therapeutics garnered heightened retail buzz on Tuesday after the firm announced preclinical results showing that its experimental drug, PAS-004, effectively blocked ETS2 signaling, which controls inflammation in IBD and other immune conditions.Research from the Francis Crick Institute found PAS-004 more effective than selumetinib at reducing the expression of ETS2-regulated genes and macrophage functions essential for cytokine production and phagocytosis.Pasithea Therapeutics shares ended Tuesday at $0.98, with a 3.77% gain, but they fell back 4.17% to $0.94 during after-hours trading.According to Lee, who published a 2024 Nature paper identifying ETS2 as an essential regulator of IBD-related inflammation, the findings suggest PAS-004 could provide broader inhibition of inflammatory pathways compared to selumetinib and therapies that target individual cytokines or rely on JAK inhibition.According to Pasithea CEO Tiago Reis Marques, data findings show PAS-004's potential for treating chronic inflammatory diseases and its existing cancer application.&nbsp;Safety data from Phase 1 trials in advanced cancer patients suggest that the drug appears to show good tolerance in wider therapeutic uses.The firm announced its plan to move PAS-004 into proof-of-concept research targeting inflammatory disorders, including IBD and ankylosing spondylitis.On Stocktwits, retail sentiment was ‘bullish’ amid a 7,450% surge in 24-hour message volume.One user&nbsp;was “infuriated” after exiting a position in Pasithea Therapeutics (KTTA) at a loss after buying in at $1.18 and selling at $0.92, only to see the stock rise afterward.<stembedurl>https://stocktwits.com/Cdeezhands/message/615259857</stembedurl>Another user noted that Pasithea’s recent news was encouraging and pointed to the stock’s price movement from around $2.08 in April to $2.48 in early May as a sign of potential for organic upside.<stembedurl>https://stocktwits.com/stocktrade77/message/615239372</stembedurl>The stock has declined 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Pasithea Therapeutics Stock Draws Retail Buzz As Early Data Shows Potential In Treating Inflammatory Diseases

The company saw increased retail chatter after new preclinical data showed its drug, PAS-004, effectively blocks inflammation pathways linked to IBD and other immune diseases. 

Equity

The company saw increased retail chatter after new preclinical data showed its drug, PAS-004, effectively blocks inflammation pathways linked to IBD and other immune diseases. The company plans to advance PAS-004 into further studies targeting inflammatory conditions.

Shares of Theriva Biologics fell sharply after the company priced a public offering of up to 6.8 million shares of common stock and accompanying warrants at $1.10 per unit.&nbsp;The offering is expected to raise nearly $7.5 million in gross proceeds, before deducting placement agent fees and other offering expenses.&nbsp;The warrants will be exercisable immediately at the same price of $1.10 per share and will expire in five years.Theriva shares closed at $0.81, down 41% on Wednesday. After hours, shares dropped to $0.75, reflecting a further 7.4% decline.The offering follows the announcement of positive topline results from the Virage Phase 2b clinical trial, which evaluated VCN-01 in combination with standard chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (PDAC).&nbsp;The study, which included 96 newly diagnosed metastatic PDAC patients, showed that patients receiving VCN-01 plus chemotherapy had a median overall survival (OS) of 10.8 months, compared to 8.6 months in the control group receiving chemotherapy alone.&nbsp;Additionally, the VCN-01+chemotherapy arm showed a median duration of response (DoR) of 11.2 months, double that of the control arm’s 5.4 months.Theriva intends to use the proceeds primarily for working capital, general corporate purposes, and research and development.&nbsp;A portion of the funds may also be used for manufacturing scale-up or potential acquisitions, although no specific deals are currently in place.&nbsp;A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.On Stocktwits, sentiment was described as ‘extremely bullish’, with ‘high’ message volume fueling speculation about the company’s future.&nbsp;One user speculated that a buyout could still be in play, potentially happening before September 30. This user noted that while the offering would dilute the stock, buying at current levels could offer significant upside in the event of a buyout.<stembedurl>https://stocktwits.com/exwallstcfo/message/613861348</stembedurl>Another user drew comparisons between Theriva and Pasithea Therapeutics, suggesting that both companies had positive news followed by public offerings.&nbsp;The user speculated that the offering could have been strategically timed to benefit from a price pump.<stembedurl>https://stocktwits.com/Staceykyusa/message/613855430</stembedurl>Shares of Theriva have fallen nearly 51% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01.

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01, in combination with standard chemotherapy. 

Shares of Pasithea Therapeutics Corp. (KTTA) soared as high as about 150% on Tuesday morning before paring back most of the gains after it announced positive data from its ongoing Phase 1 trial of PAS-004 in advanced cancer patients.PAS-004 is a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other mitogen-activated protein kinase (MAPK) pathway driven cancer indications.The clinical-stage biotechnology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/06/3074902/0/en/Pasithea-Therapeutics-Reports-Positive-Pharmacodynamic-Results-Demonstrating-Robust-Target-Engagement-from-its-Ongoing-Phase-1-Clinical-Trial-of-PAS-004.html">said</a> that several patients achieved stable disease and tumor shrinkage while on the treatment.A patient being treated with 15-milligram capsules of PAS-004 with stage 4 pancreatic cancer achieved a tumor volume reduction of 9.8% over 5 months of PAS-004 treatment, the company said. The patients currently remain in the study, it added.Certain biomarkers also confirmed the capsule’s MEK inhibitor activity and substantial target engagement, the company said.The Phase 1 trial is aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004 in patients with MAPK pathway-driven advanced solid tumors.The recently announced data include results from patients treated with 8mg, 15mg, and 4mg tablets of PAS-004.In April, the company also dosed three subjects with 30mg capsules of PAS-004.The company then said it expects to complete enrollment of all patients in the trial by the end of 2025.On Stocktwits, retail sentiment around Pasithea jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:633/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_06_at_10_44_26_AM_png_4ec77b8998.webp" alt="KTTA's Sentiment Meter and Message Volume as of 10:45 a.m. ET on May 6, 2025 | Source: Stocktwits" width="633" height="62"><figcaption>KTTA's Sentiment Meter and Message Volume as of 10:45 a.m. ET on May 6, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/KTTA">KTTA stock</a> is down by about 42% this year and by about 76% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/economist-kenneth-rogoff-believes-trump-trade-policy-is-speeding-up-dollar-decline/chiIJtJRbS7">Economist Kenneth Rogoff Believes Trump’s Trade Policy Is Speeding Up Dollar’s Decline, Calls Navarro President’s ‘Rasputin’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated

The clinical-stage biotechnology company said several patients achieved stable disease and tumor shrinkage while on the treatment.

Shares of Pasithea Therapeutics Corp. (KTTA) surged nearly 47% on Thursday, closing at a two-month high, after an external committee approved advancing its cancer drug trial to the next dosing cohort.The news also resulted in the company's stock drawing the highest jump in retail investor chatter among healthcare stocks on Stocktwits.&nbsp;Message volume about KTTA soared by a whopping 48,000% by late Thursday, while sentiment flipped to 'extremely bullish' from 'bearish' a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/KTTA_sentiment_and_message_volume_April_10_png_57f0ce9213.webp" alt="KTTA sentiment and message volume April 10.png" width="1318" height="316"><figcaption>KTTA sentiment and message volume April 10. | source: Stocktwits</figcaption></figure>Pasithea said that its Phase 1 clinical trial of PAS-004 for advanced cancer has been cleared to advance to Cohort 6 (30mg capsule), following a recommendation from the independent Safety Review Committee.&nbsp;The decision was based on safety data from three patients in Cohort 5, with no dose-limiting toxicities (DLTs) reported.Notably, none of the first 19 patients — across both capsule and tablet formulations — have experienced rash, a common and often dose-limiting side effect seen with competitor MEK inhibitors.The ongoing trial is a multi-center, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004.&nbsp;One bullish watcher said the stock "will probably open at $2.18" on Friday, implying a more than 35% jump from the last close.<stembedurl>https://stocktwits.com/Nifty_Trader/message/611306648</stembedurl>Another user recommended holding the stock for a week or two and it "should be at $5 or $7."<stembedurl>https://stocktwits.com/MommoTrader/message/611306390</stembedurl><a href="https://stocktwits.com/symbol/KTTA">Pasithea stock</a> has lost nearly 50% this year. Shares were up marginally in Thursday's after-hours trading.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort

The decision was based on safety data from three patients in Cohort 5, with no dose-limiting toxicities reported.

11 Undervalued Stocks for Less Than $50 in April 2024

These inexpensive and undervalued stocks are top performers with strong upside potential based on their price-to-book ratio

 Steve Russell / Contributor

Neuroscience-focused biotechnology firm...

Pasithea Therapeutics Corp trading halted, volatility trading pause

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern...

Pasithea Therapeutics announces invention of crystalline form of PAS-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio -- SOUTH SAN FRANCISCO...

Pasithea Therapeutics announces FDA acceptance of IND application for PAS-004

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Lawrence J. Steinman on May 12, 2020 and is headquartered in Miami Beach, FL.

Pasithea Therapeutics Corp

Buying

Selling or trimming

Holding

Watching from the sidelines

What are you doing with $UBER stock on the post-earnings sell-off?

Current Price	$0.7525
Prev Close	$0.8159
Open	$0.815
Dividend Yield	0.00%
50-Day Moving Average	$0.7623
Beta	-0.04
Avg. Volume	98,340.17
PE Ratio	-0.11

52-Week High	$4.35
52-Week Low	$0.65
Market Capitalization	$6.07M
EPS (Annual)	-$12.69
Price to Book	0.40
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

KTTA
Pasithea Therapeutics Corp

Feed

News

Sentiment

Fundamentals

Info

Latest KTTA News

KTTAPasithea Therapeutics Corp